ValirX Gets US Patent For Proposed VAL201 Cancer Treatment

20th Mar 2018 13:55

LONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.

VAL201, which is currently in clinical trials, is a potential treatment for prostate cancer and other solid tumours.

The patent, ValirX said, covers the molecule and use of compounds as well as a wide range of derivatives, modifications, and analogues of the compounds.

ValirX currently has patents for VAL201 in Europe, Japan, Australia, the UK, as well as one already in the US.

Chief Executive Satu Vainikka said: "I am delighted that VAL201 is now in receipt of a US patent grant and it comes at an opportune time for the company and shortly after we received approval from the UK Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for the company to expand its VAL201 trial to more speedily reach VAL201's full therapeutic potential and potential anti-cancer impact."

Shares were down 11% on Tuesday at a price of 3.35 pence each.

---

Related Shares:

ValiRx